Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Needham Maintains Buy on Sarepta Therapeutics, Raises Price Target to $162

Needham analyst Gil Blum maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Buy and raises the price target from $150 to $162.
byBenzinga Newsdesk
July 29, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Needham analyst Gil Blum maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Buy and raises the price target from $150 to $162.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0